On Tuesday, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) opened lower -4.24% from the last session, before settling in for the closing price of $3.54. Price fluctuations for RCKT have ranged from $2.19 to $22.01 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -11.60% over the last five years. Company’s average yearly earnings per share was noted 25.24% at the time writing. With a float of $98.89 million, this company’s outstanding shares have now reached $107.88 million.
Rocket Pharmaceuticals Inc (RCKT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Rocket Pharmaceuticals Inc is 8.35%, while institutional ownership is 85.60%. The most recent insider transaction that took place on Aug 18 ’25, was worth 2,142. In this transaction an insider of this company sold 699 shares at a rate of $3.06, taking the stock ownership to the 56,285 shares. Before that another transaction happened on Aug 19 ’25, when Company’s insider sold 361 for $3.00, making the entire transaction worth $1,082. This insider now owns 55,924 shares in total.
Rocket Pharmaceuticals Inc (RCKT) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.71 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.75) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.15% during the next five years compared to -11.60% drop over the previous five years of trading.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Trading Performance Indicators
Check out the current performance indicators for Rocket Pharmaceuticals Inc (RCKT). In the past quarter, the stock posted a quick ratio of 6.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.21 in one year’s time.
Technical Analysis of Rocket Pharmaceuticals Inc (RCKT)
Analysing the last 5-days average volume posted by the [Rocket Pharmaceuticals Inc, RCKT], we can find that recorded value of 16.88 million was better than the volume posted last year of 3.73 million. As of the previous 9 days, the stock’s Stochastic %D was 53.23%.
During the past 100 days, Rocket Pharmaceuticals Inc’s (RCKT) raw stochastic average was set at 19.77%, which indicates a significant decrease from 44.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was lower than the 0.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.02, while its 200-day Moving Average is $7.74. Now, the first resistance to watch is $3.49. This is followed by the second major resistance level at $3.59. The third major resistance level sits at $3.66. If the price goes on to break the first support level at $3.32, it is likely to go to the next support level at $3.24. Should the price break the second support level, the third support level stands at $3.14.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Key Stats
There are currently 107,904K shares outstanding in the company with a market cap of 365.79 million. Presently, the company’s annual sales total 0 K according to its annual income of -258,750 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -68,920 K.
